Targeting ryanodine receptor type 2 to mitigate chemotherapy-induced neurocognitive impairments in mice
Authors:
- Yang LiuYLYang Liu
- Steven ReikenSRSteven Reiken
- Haikel DridiHDHaikel Dridi
- Khalid S. MohammadKhalid S. Mohammad
- Trupti TrivediTTTrupti Trivedi
- Marco C. MiottoMMMarco C. Miotto
- Kaylee Wedderburn-PughKWKaylee Wedderburn-Pugh
- Leah SittenfeldLSLeah Sittenfeld
- Ynez KerleyYKYnez Kerley
- Jill A. MeyerJMJill A. Meyer
- 27 September 2023
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (715) , eadf8977
Abstract
Chemotherapy-induced cognitive dysfunction (chemobrain) is an important adverse sequela of chemotherapy. Chemobrain has been identified by the National Cancer Institute as a poorly understood problem for which current management or treatment strategies are limited or ineffective. Here, we show that chemotherapy treatment with doxorubicin (DOX) in a breast cancer mouse model induced protein kinase A (PKA) phosphorylation of the neuronal ryanodine receptor/calcium (Ca2+) channel type 2 (RyR2), RyR2 oxidation, RyR2 nitrosylation, RyR2 calstabin2 depletion, and subsequent RyR2 Ca2+leakiness. Chemotherapy was furthermore associated with abnormalities in brain glucose metabolism and neurocognitive dysfunction in breast cancer mice. RyR2 leakiness and cognitive dysfunction could be ameliorated by treatment with a small molecule Rycal drug (S107). Chemobrain was also found in noncancer mice treated with DOX or methotrexate and 5-fluorouracil and could be prevented by treatment with S107. Genetic ablation of the RyR2 PKA phosphorylation site (RyR2-S2808A) also prevented the development of chemobrain. Chemotherapy increased brain concentrations of the tumor necrosis factor–α and transforming growth factor–β signaling, suggesting that increased inflammatory signaling might contribute to oxidation-driven biochemical remodeling of RyR2. Proteomics and Gene Ontology analysis indicated that the signaling downstream of chemotherapy-induced leaky RyR2 was linked to the dysregulation of synaptic structure–associated proteins that are involved in neurotransmission. Together, our study points to neuronal Ca2+dyshomeostasis via leaky RyR2 channels as a potential mechanism contributing to chemobrain, warranting further translational studies.Keywords
This publication has 128 references indexed in Scilit:
- Structural synaptic elements are differentially regulated in superior temporal cortex of schizophrenia patientsEuropean Archives of Psychiatry and Clinical Neuroscience, 2012
- Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modificationsBMC Neuroscience, 2011
- Longitudinal Assessment of Cognitive Changes Associated With Adjuvant Treatment for Breast Cancer: Impact of Age and Cognitive ReserveJournal of Clinical Oncology, 2010
- Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrainNeuroscience, 2010
- Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscleNature Medicine, 2009
- Remodeling of ryanodine receptor complex causes “leaky” channels: A molecular mechanism for decreased exercise capacityProceedings of the National Academy of Sciences, 2008
- Cognitive function in breast cancer patients prior to adjuvant treatmentBreast Cancer Research and Treatment, 2007
- Candidate mechanisms for chemotherapy-induced cognitive changesNature Reviews Cancer, 2007
- Dysfunction of TGF-β signaling in Alzheimer’s diseaseJournal of Clinical Investigation, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005